DF Dent & Co. Inc. lifted its position in shares of Illumina, Inc. (NASDAQ:ILMN) by 10.1% during the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 467,789 shares of the life sciences company’s stock after purchasing an additional 42,768 shares during the period. Illumina comprises 2.1% of DF Dent & Co. Inc.’s investment portfolio, making the stock its 23rd largest holding. DF Dent & Co. Inc. owned approximately 0.32% of Illumina worth $81,171,000 at the end of the most recent quarter.
Other large investors have also recently added to or reduced their stakes in the company. Penserra Capital Management LLC grew its holdings in shares of Illumina by 13.0% during the second quarter. Penserra Capital Management LLC now owns 884 shares of the life sciences company’s stock worth $153,000 after purchasing an additional 102 shares during the last quarter. Paradigm Asset Management Co. LLC grew its holdings in shares of Illumina by 5.6% during the second quarter. Paradigm Asset Management Co. LLC now owns 950 shares of the life sciences company’s stock worth $165,000 after purchasing an additional 50 shares during the last quarter. Patten Group Inc. grew its holdings in shares of Illumina by 2.7% during the first quarter. Patten Group Inc. now owns 965 shares of the life sciences company’s stock worth $166,000 after purchasing an additional 25 shares during the last quarter. NN Investment Partners Holdings N.V. grew its holdings in shares of Illumina by 11.3% during the second quarter. NN Investment Partners Holdings N.V. now owns 985 shares of the life sciences company’s stock worth $171,000 after purchasing an additional 100 shares during the last quarter. Finally, Birch Hill Investment Advisors LLC bought a new stake in shares of Illumina during the first quarter worth about $205,000. Institutional investors own 93.32% of the company’s stock.
ILLEGAL ACTIVITY NOTICE: This piece was first posted by Community Financial News and is the sole property of of Community Financial News. If you are viewing this piece on another domain, it was illegally stolen and reposted in violation of US & international copyright legislation. The original version of this piece can be accessed at https://www.com-unik.info/2017/10/10/df-dent-co-inc-grows-stake-in-illumina-inc-ilmn.html.
In other Illumina news, EVP Marc Stapley sold 2,000 shares of the stock in a transaction on Friday, July 14th. The stock was sold at an average price of $173.56, for a total transaction of $347,120.00. Following the sale, the executive vice president now owns 39,941 shares of the company’s stock, valued at approximately $6,932,159.96. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, SVP Oene Mark Van sold 9,729 shares of the stock in a transaction on Tuesday, September 12th. The shares were sold at an average price of $211.33, for a total value of $2,056,029.57. Following the sale, the senior vice president now directly owns 24,908 shares in the company, valued at approximately $5,263,807.64. The disclosure for this sale can be found here. Over the last three months, insiders have sold 178,516 shares of company stock valued at $34,995,591. 1.60% of the stock is owned by corporate insiders.
Illumina (NASDAQ:ILMN) last released its quarterly earnings results on Tuesday, August 1st. The life sciences company reported $0.82 earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of $0.68 by $0.14. Illumina had a return on equity of 19.69% and a net margin of 30.27%. The business had revenue of $662.00 million during the quarter, compared to analyst estimates of $642.38 million. During the same quarter in the previous year, the company posted $0.86 earnings per share. Illumina’s revenue for the quarter was up 10.3% on a year-over-year basis. On average, equities research analysts forecast that Illumina, Inc. will post $3.65 EPS for the current fiscal year.
Several research firms have recently weighed in on ILMN. First Analysis upgraded Illumina from an “underweight” rating to an “equal weight” rating and set a $176.00 price target on the stock in a report on Wednesday, August 2nd. Zacks Investment Research cut Illumina from a “buy” rating to a “hold” rating in a report on Friday, August 4th. Barclays PLC restated an “equal weight” rating and set a $150.00 price target on shares of Illumina in a report on Wednesday, August 9th. Canaccord Genuity restated a “hold” rating and set a $170.00 price target on shares of Illumina in a report on Wednesday, July 26th. Finally, BidaskClub cut Illumina from a “hold” rating to a “sell” rating in a report on Thursday, August 17th. Three equities research analysts have rated the stock with a sell rating, ten have assigned a hold rating and eleven have given a buy rating to the company. The company currently has an average rating of “Hold” and a consensus price target of $184.86.
Illumina, Inc (Illumina) is a provider of sequencing- and array-based solutions for genetic analysis. The Company operates through two segments: Core Illumina and the consolidated variable interest entities (VIEs), which include the activities of GRAIL, Inc (GRAIL) and Helix Holdings I, LLC (Helix). Core Illumina consists of its core operations.
What are top analysts saying about Illumina Inc.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Illumina Inc. and related companies.